Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Principles of cancer therapy: oncogene and non-oncogene addiction.

Luo J, Solimini NL, Elledge SJ.

Cell. 2009 Mar 6;136(5):823-37. doi: 10.1016/j.cell.2009.02.024. Erratum in: Cell. 2009 Aug 21;138(4):807.

2.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK.

Nat Med. 2008 Dec;14(12):1351-6. doi: 10.1038/nm.1890. Epub 2008 Nov 30.

3.

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, Rouyrre N, Trommeshauser D, Hoesl CE, Munzert G.

J Clin Oncol. 2008 Dec 1;26(34):5511-7. doi: 10.1200/JCO.2008.16.1547. Epub 2008 Oct 27.

PMID:
18955456
4.

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.

Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG.

Nat Med. 2008 Aug;14(8):822-7. doi: 10.1038/nm.1790. Epub 2008 Jul 20.

5.

Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery.

Macůrek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, Clouin C, Taylor SS, Yaffe MB, Medema RH.

Nature. 2008 Sep 4;455(7209):119-23. doi: 10.1038/nature07185. Epub 2008 Jul 9.

PMID:
18615013
6.

Ras oncogenes: split personalities.

Karnoub AE, Weinberg RA.

Nat Rev Mol Cell Biol. 2008 Jul;9(7):517-31. doi: 10.1038/nrm2438. Review.

7.

Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry.

Seki A, Coppinger JA, Jang CY, Yates JR, Fang G.

Science. 2008 Jun 20;320(5883):1655-8. doi: 10.1126/science.1157425.

8.

Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1.

Petronczki M, Lénárt P, Peters JM.

Dev Cell. 2008 May;14(5):646-59. doi: 10.1016/j.devcel.2008.04.014. Review.

9.

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.

Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T.

Nat Genet. 2008 May;40(5):600-8. doi: 10.1038/ng.115. Epub 2008 Mar 30.

10.

The RASSF1A tumor suppressor restrains anaphase-promoting complex/cyclosome activity during the G1/S phase transition to promote cell cycle progression in human epithelial cells.

Whitehurst AW, Ram R, Shivakumar L, Gao B, Minna JD, White MA.

Mol Cell Biol. 2008 May;28(10):3190-7. doi: 10.1128/MCB.02291-07. Epub 2008 Mar 17.

11.

Cancer proliferation gene discovery through functional genomics.

Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, Westbrook TF, Liang AC, Chang K, Hackett JA, Harper JW, Hannon GJ, Elledge SJ.

Science. 2008 Feb 1;319(5863):620-4. doi: 10.1126/science.1149200. Erratum in: Science.2008 Apr 18;320(5874):316.

12.

Profiling essential genes in human mammary cells by multiplex RNAi screening.

Silva JM, Marran K, Parker JS, Silva J, Golding M, Schlabach MR, Elledge SJ, Hannon GJ, Chang K.

Science. 2008 Feb 1;319(5863):617-20. doi: 10.1126/science.1149185.

13.

Non-oncogene addiction and the stress phenotype of cancer cells.

Solimini NL, Luo J, Elledge SJ.

Cell. 2007 Sep 21;130(6):986-8.

14.

Cancer cells and normal cells differ in their requirements for Thoc1.

Li Y, Lin AW, Zhang X, Wang Y, Wang X, Goodrich DW.

Cancer Res. 2007 Jul 15;67(14):6657-64.

15.

Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen.

Morgan-Lappe SE, Tucker LA, Huang X, Zhang Q, Sarthy AV, Zakula D, Vernetti L, Schurdak M, Wang J, Fesik SW.

Cancer Res. 2007 May 1;67(9):4390-8.

16.

Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair.

Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER 3rd, Hurov KE, Luo J, Ballif BA, Gygi SP, Hofmann K, D'Andrea AD, Elledge SJ.

Cell. 2007 Apr 20;129(2):289-301. Epub 2007 Apr 5.

17.

A direct link of the Mos-MAPK pathway to Erp1/Emi2 in meiotic arrest of Xenopus laevis eggs.

Inoue D, Ohe M, Kanemori Y, Nobui T, Sagata N.

Nature. 2007 Apr 26;446(7139):1100-4. Epub 2007 Apr 4.

PMID:
17410130
18.

Phosphorylation of Erp1 by p90rsk is required for cytostatic factor arrest in Xenopus laevis eggs.

Nishiyama T, Ohsumi K, Kishimoto T.

Nature. 2007 Apr 26;446(7139):1096-9. Epub 2007 Apr 4.

PMID:
17410129
19.

Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition.

Wang R, He G, Nelman-Gonzalez M, Ashorn CL, Gallick GE, Stukenberg PT, Kirschner MW, Kuang J.

Cell. 2007 Mar 23;128(6):1119-32.

20.

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ.

Curr Biol. 2007 Feb 20;17(4):316-22. Epub 2007 Feb 8.

Supplemental Content

Support Center